Washington D.C. – May 12, 2026 – The U.S. Food and Drug Administration (FDA) is navigating a significant leadership transition as Commissioner Martin Makary has resigned, concluding a period marked by considerable upheaval and strategic redirection. Stepping into the acting commissioner role is Kyle Diamantis, formerly the agency’s deputy commissioner for food. This change comes at a critical juncture for the regulatory body, which has faced intense scrutiny and shifting priorities under Makary’s leadership.

President Trump confirmed Makary’s departure, a move first reported by Politico, during a press briefing on Tuesday. "Marty’s a great guy, he’s a friend of mine, and he’s a wonderful man," Trump stated. "He was having some difficulty, but he’s going to go on and he’s going to do well. Everybody wants that job." The Department of Health and Human Services (HHS) has not yet responded to requests for further comment on the resignation.

The appointment of Diamantas signals a potential intensification of the "Make America Healthy Again" (MAHA) agenda, a cornerstone of Health and Human Services Secretary Robert F. Kennedy’s policy initiatives. Diamantas, a trusted ally of Secretary Kennedy, has been instrumental in driving key food-related policy changes. His prior role as senior counselor within HHS, a position he assumed in February, was explicitly designed to "help us move faster and go further as we work to Make America Healthy Again."

A Deep Dive into the Transition

The resignation of Commissioner Martin Makary marks the end of what has been described as an "unusually tumultuous run" at the helm of one of the nation’s most critical health regulatory agencies. Makary, a prominent medical researcher and author known for his work on patient safety and healthcare costs, was nominated by President Trump in November 2024. His confirmation hearing in March 2025 proceeded smoothly, and he was seen as a more traditional choice to lead the FDA.

However, Makary’s tenure has been characterized by significant challenges and controversies. Multiple high-ranking officials resigned amidst widespread layoffs, creating an atmosphere of uncertainty within the agency. Analysts observed a noticeable increase in delayed drug reviews, a trend that deviated from previous years and raised concerns among pharmaceutical stakeholders. Furthermore, the FDA under Makary’s leadership experienced what some described as "unpredictable shifts in guidance and regulatory rejections," a situation that frustrated drugmakers and appeared to conflict with Makary’s stated goals of fostering regulatory flexibility.

Paul Matteis, an analyst at the investment firm Stifel, noted the heightened unpredictability. "Really the broader takeaway here for us is that FDA – and our ability to predict the FDA – is about as uncertain as it’s been in the past decade or longer," he wrote in a client note late last year.

Kyle Diamantis: A New Era for Food Policy at the FDA

The selection of Kyle Diamantas as acting commissioner suggests a strategic pivot, placing a strong emphasis on the food and nutrition portfolio. Diamantas has a proven track record of advancing Secretary Kennedy’s public health agenda, particularly in areas related to food policy. His prior work has included overseeing significant changes to the U.S. Dietary Guidelines and championing efforts to formally define "ultraprocessed foods." He has also been a vocal advocate for encouraging the food industry to transition away from artificial dyes and to scrutinize the Generally Recognized as Safe (GRAS) approval process for food chemicals.

This focus on food policy is particularly significant given its growing resonance with the electorate. Unlike issues such as vaccine mandates or abortion medication restrictions, food policy and its impact on public health appear to be gaining traction among voters. This alignment could position food as a central pillar of the FDA’s future initiatives and a key component of the MAHA agenda.

The FDA’s most recent budget request underscored this burgeoning focus. The agency sought an additional $57 million for its food programs, with a significant portion earmarked for MAHA initiatives. These initiatives include a comprehensive overhaul of the GRAS process, a system that has faced considerable criticism from Secretary Kennedy for perceived loopholes and inadequate oversight. An analysis from Akim Gump highlights the ambitious nature of these proposed changes.

Chronology of Commissioner Makary’s Tenure and the Road to Transition

November 2024: President Trump nominates Dr. Martin Makary, a renowned surgeon and author, to lead the Food and Drug Administration. The nomination is met with anticipation, with many expecting a return to a more traditional approach to regulatory leadership.

March 2025: Dr. Makary successfully navigates his Congressional confirmation hearing, securing the position of FDA Commissioner. His academic background and established reputation in the medical community are seen as strengths.

Spring 2025 – Early 2026: The FDA experiences a period of significant internal restructuring and staff reductions, leading to the departure of several key officials. This wave of layoffs creates an environment of uncertainty within the agency.

Throughout 2025-2026: Reports emerge of an increase in delayed drug reviews, prompting concern among pharmaceutical companies and investors. The FDA’s regulatory guidance becomes increasingly unpredictable, leading to frustration among industry stakeholders. Analysts begin to question the agency’s consistency and predictability.

Early 2026: Commissioner Makary faces mounting pressure from various groups. He reportedly draws criticism from anti-abortion organizations for a perceived lack of urgency in addressing concerns surrounding the abortion pill mifepristone and for approving a generic version of the drug. Simultaneously, President Trump is reported to have pressured Makary to expedite the approval of flavored vaping products, a move Makary had previously hesitated on due to public health concerns.

May 12, 2026: Politico reports on Commissioner Makary’s resignation. President Trump confirms the departure, appointing Kyle Diamantis as acting commissioner.

Supporting Data and Broader Trends

The leadership transition at the FDA occurs against a backdrop of evolving public health priorities and increasing political engagement on issues related to food and diet. The "Make America Healthy Again" agenda, championed by Secretary Kennedy, has placed a significant emphasis on preventative health measures, nutritional guidance, and the regulation of food products.

Recent polling data, such as that from the KFF Health Tracking Poll, suggests that issues related to food and health are resonating more strongly with voters than some other contentious public health matters. This growing public awareness and concern create a fertile ground for policy initiatives aimed at improving dietary habits and addressing the health impacts of food consumption.

The FDA’s proposed budget for fiscal year 2027 reflects this shift, with a substantial increase in funding requested for its food programs. This allocation signals a commitment to bolstering the agency’s capacity to address complex food-related challenges, including:

• Revitalizing the GRAS Process: The current GRAS system, which allows food ingredients to be deemed safe without premarket approval from the FDA if they meet certain criteria, has been a persistent point of contention. Secretary Kennedy and others have argued that the process is susceptible to industry influence and may not adequately protect public health. The proposed funding aims to strengthen oversight and scientific review within this framework.
• Defining and Regulating Ultra-Processed Foods: The classification and regulation of ultra-processed foods are gaining momentum as a public health strategy. Diamantas’s prior advocacy in this area suggests a potential move towards clearer guidelines and possibly restrictions on certain types of processed foods linked to adverse health outcomes.
• Phasing Out Artificial Ingredients: The push to move away from artificial dyes and synthetic colors in food products is another area where Diamantas has been actively involved. This initiative aligns with a broader consumer trend towards more natural and less-processed food options.

The financial implications of these initiatives are substantial. The $57 million in requested additional funding for the foods program represents a significant investment in the FDA’s ability to execute on these ambitious policy goals.

Official Responses and Perspectives

While the Department of Health and Human Services has remained silent on Makary’s resignation, President Trump’s comments provide some insight into the administration’s perspective. His remarks suggest a cordial departure, emphasizing Makary’s positive personal attributes while acknowledging the "difficulties" he encountered. The President’s assertion that "everybody wants that job" highlights the high-stakes and often politically charged nature of the FDA commissioner position.

The appointment of Kyle Diamantas is likely to be viewed favorably by proponents of the MAHA agenda. His prior experience and close association with Secretary Kennedy suggest a continuation and potential acceleration of policies focused on food and nutrition. His supporters will likely point to his experience in shaping dietary guidelines and his proactive approach to food safety and regulation as qualifications for the acting commissioner role.

Conversely, pharmaceutical and biotech industries, which have navigated a period of regulatory uncertainty under Makary, will be watching closely for signs of how the FDA’s priorities might shift under new leadership. The concerns raised by analysts regarding unpredictable guidance and regulatory rejections will likely persist until a clearer direction and more consistent approach emerge.

Implications for the Future of the FDA

The departure of Commissioner Makary and the interim appointment of Kyle Diamantas signal a potential recalibration of the FDA’s strategic direction. The increased emphasis on food policy suggests that the agency may become a more significant player in public health initiatives related to diet, nutrition, and the regulation of food products.

For the food industry, this transition could bring about more stringent regulations and increased scrutiny, particularly concerning ingredients, processing methods, and labeling. Companies that have been proactive in aligning with healthier food trends and transparent practices may find themselves better positioned to adapt to evolving regulatory landscapes.

The pharmaceutical and medical device sectors, while not the primary focus of Diamantas’s prior work, will also be observing the broader impact of this leadership change. The agency’s overall capacity for efficient review and clear guidance will remain a critical factor for innovation and market access in these industries.

The "unusually tumultuous" period under Makary’s leadership has underscored the inherent challenges of managing a vast and complex regulatory agency operating at the intersection of science, public health, and politics. The coming months will reveal the extent to which Diamantas can bring stability and strategic focus to the FDA, while simultaneously advancing the administration’s ambitious public health agenda. The agency’s ability to navigate these transitions effectively will be crucial in maintaining public trust and ensuring the safety and efficacy of the products it oversees.